Diagnosis of acute myeloid leukemia according to the WHO classification in the Japan Adult Leukemia Study Group AML-97 protocol

International Journal of Hematology

Volumn 87, Issue 2, 2008, Pages 144-151

  Wakui, Moe ^a   Kuriyama, Kazutaka ^a   Miyazaki, Yasushi ^b   Hata, Tomoko ^b   Taniwaki, Masafumi ^c   Ohtake, Shigeki ^d   Sakamaki, Hisashi ^e   Miyawaki, Shuichi ^f   Naoe, Tomoki ^g   Ohno, Ryuzo ^h   Tomonaga, Masao ^b  

^a UNIVERSITY OF THE RYUKYUS   (Japan)

^b NAGASAKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

^d KANAZAWA UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCE   (Japan)

^e TOKYO METROPOLITAN KOMAGOME HOSPITAL   (Japan)

^f SAISEIKAI MAEBASHI HOSPITAL   (Japan)

^g NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^h AICHI CANCER CENTER HOSPITAL   (Japan)

Author keywords

11q23 abnormalities; AML; Multilineage dyplasia; Myeloperoxidase; WHO classification

Indexed keywords

CYTARABINE; IDARUBICIN; MYELOPEROXIDASE;

ACUTE GRANULOCYTIC LEUKEMIA; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; BLAST CELL; CHROMOSOME 11Q; CHROMOSOME ABERRATION; CHROMOSOME ANALYSIS; COMBINATION CHEMOTHERAPY; DISEASE CLASSIFICATION; DYSPLASIA; GENETIC DISORDER; HUMAN; KARYOTYPE; OUTCOME ASSESSMENT; RECURRENT DISEASE; REMISSION; REVIEW; SURVIVAL RATE; THROMBOCYTE COUNT; WORLD HEALTH ORGANIZATION;

ADOLESCENT; ADULT; AGED; FEMALE; HUMANS; JAPAN; KAPLAN-MEIER ESTIMATE; KARYOTYPING; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; REGISTRIES;

EID: 42049120504     PISSN: 09255710     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12185-008-0025-3     Document Type: Review

References (35)

1. Bennett JM, Catovsky D, Daniel MT, et al. Proposals for the classification of acute leukaemias. French-American-British (FAB) co-operative group. Br J Haematol. 1976;33:451-8.
2. Bennett JM, Catovsky D, Daniel MT, et al. Proposed revised criteria for the classification of acute myeloid leukemia: a report of the French-American-British Cooperative Group. Ann Intern Med. 1985;103:620-5.
3. Grimwade D, Walker H, Oliver F, et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. Blood. 1998;92:2322-33.
4. Harris NL, Jaffe ES, Diebold J, et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. J Clin Oncol. 1999;17:3835-49.
5. Vardiman JW, Harris NL, Brunning RD. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood. 2002;100:2292-302.
6. Brunning RD, Matutes E, Harris NL, et al. Acute myeloid leukaemias. In: Jaffe ES, Harris NL, Stein H, Vardiman JW (eds) Pathology and genetics of tumors of haematopoietic and lymphoid tissues. Lyon: IARC Press; 2001. p. 75-107.
7. Grimwade D, Walker H, Harrison G, et al. The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML 11 trial. Blood. 2001;98:1312-20.
8. Slovak ML, Kopecky KJ, Cassileth PA, et al. Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group study. Blood. 2000;96:4075-83.
9. Rowe JM, Liesveld JL. Treatment and prognostic factors in acute myeloid leukaemia. Baillieres Clin Haematol. 1996;9:87-105.
10. Schoch C, Kern W, Schnittger S, Buchner T, Hiddemann W, Haferlach T. The influence of age on prognosis of de novo acute myeloid leukemia differs according to cytogenetic subgroups. Haematologica. 2004;89:1082-90.
11. Arber DA, Stein AS, Carter NH, Ikle D, Forman SJ, Slovak ML. Prognostic impact of acute myeloid leukemia classification: importance of detection of recurring cytogenetic abnormalities and multilineage dysplasia on survival. Am J Clin Pathol. 2003;119:672-80.
12. Bloomfield CD, Shuma C, Regal L, et al. Long-term survival of patients with acute myeloid leukemia: a third follow-up of the Fourth International Workshop on Chromosomes in Leukemia. Cancer. 1997;80:2191-8.
13. Schoch C, Schnittger S, Klaus M, Kern W, Hiddemann W, Haferlach T. AML with 11q23/MLL abnormalities as defined by the WHO classification: incidence, partner chromosomes, FAB subtype, age distribution, and prognostic impact in an unselected series of 1897 cytogenetically analyzed AML cases. Blood. 2003;102:2395-402.
14. Dohner K, Tobis K, Ulrich R, et al. Prognostic significance of partial tandem duplications of the MLL gene in adult patients 16 to 60 years old with acute myeloid leukemia and normal cytogenetics: a study of the Acute Myeloid Leukemia Study Group Ulm. J Clin Oncol. 2002;20:3254-61.
15. Byrd JC, Mrozek K, Dodge RK, et al. Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). Blood. 2002;100:4325-36.
16. Mitterbauer-Hohendanner G, Mannhalter C. The biological and clinical significance of MLL abnormalities in haematological malignancies. Eur J Clin Invest. 2004;34:12-24.
17. Miyawaki S, Sakamaki H, Ohtake S, et al. A randomized, postremission comparison of four courses of standard-dose consolidation therapy without maintenance therapy versus three courses of standard-dose consolidation with maintenance therapy in adults with acute myeloid leukemia: the Japan Adult Leukemia Study Group AML97 study. Cancer. 2005;104:2726-34.
18. Miyazaki Y, Kuriyama K, Miyawaki S, et al. Cytogenetic heterogeneity of acute myeloid leukemia (AML) with trilineage dysplasia: Japan Adult Leukemia Study Group-AML 92 study. Br J Haematol. 2003;120:56-62.
19. Matsuo T, Kuriyama K, Miyazaki Y, et al. The percentage of myeloperoxidase-positive blast cells is a strong independent prognostic factor in acute myeloid leukemia, even in the patients with normal karyotype. Leukemia. 2003;17:1538-43.
20. Arber DA, Stein AS, Carter NH, Ilie D, Forman SJ, Slovak ML. Prognostic impact of acute myeloid leukemia classification. Am J Clin Pathol. 2003;119:672-80.
21. Yanada M, Suzuki M, Kawashima K, et al. Long-term outcomes for unselected patients with acute myeloid leukemia categorized according to the World health Organization classification: a single-center experience. Eur J Haematol. 2005;74:418-23.
22. Bao L, Wang X, Ryder J, et al. Prospective study of 174 de novo acute myelogenous leukemias according to the WHO classification: subtypes, cytogenetic features and FLT3 mutations. Eur J Haematol. 2006;77:35-45.
23. Mayer-Monard S, Parlier J, Passweg J, et al. Combination of broad molecular screening and cytogenetic analysis for genetic risk assignment and diagnosis in patients with acute leukemia. Leukemia. 2006;20:247-53.
24. Olesen LH, Clausen N, Dimitrijevic A, Kerndrup G, Kjeldsen E, Hokland P. Prospective application of a multiplex reverse transcription-polymerase chain reaction assay for the detection of balanced translocations in leukaemia: a single-laboratory study of 390 paediatric and adult patients. Br J Haematol. 2004;127:59-66.
25. Kuriyama K, Tomonaga M, Matsuo T, et al. Poor response to intensive chemotherapy in de novo acute myeloid leukaemia with trilineage myelodysplasia. Br J Haematol. 1994;86:767-73.
26. Haferlach T, Schoch C, Loffler H, et al. Morphologic dysplasia in de novo acute myeloid leukemia (AML) is related to unfavorable cytogenetics but has no independent prognostic relevance under the conditions of intensive induction therapy: results of a multiparameter analysis from the German AML Cooperative Group studies. J Clin Oncol. 2003;21:256-65.
27. Martineau M, Berger R, Lillington DM, Moorman AV, Secker-Walker LM. The t(6;11)(q27;q23) translocation in acute leukemia: a laboratory and clinical study of 30 cases. Leukemia. 1998;12:788-91.
28. Dreyling MH, Schrader K, Fonatsch C, et al. MLL and CALM are fused to AF10 in morphologically distinct subsets of acute leukemia with translocation t(10;11): both rearrangements are associated with a poor prognosis. Blood. 1998;91:4662-7.
29. Scholl C, Schlenk RF, Eiwen K, Dohner H, Frohlin S, Dohner K. The prognostic value of MLL-AF9 detection in patients with t(9;11)(p22;q23)-positive acute myeloid leukemia. Haematologica. 2005;90:1626-34.
30. Mrozek K, Heinonen K, Lawrence D, et al. Adult patients with de novo acute myeloid leukemia and t(9;11)(p22;q23) have a superior outcome to patients with other translocations involving band 11q23: a Cancer and Leukemia Group B study. Blood. 1997;90:4532-8.
31. Pasqualucci L, Liso A, Martelli PM, et al. Mutated nucleophosmin detects clonal multilineage involvement in acute myeloid leukemia: impact on WHO classification. Blood. 2006;108:4146-55.
32. Choudhary C, Schwable J, Brandts C, et al. AML-associated Flt3 kinase domain mutations show signal translocation differences compared with Flt3 ITD mutations. Blood. 2005;106:265-73.
33. Bienz M, Ludwig M, Mueller BU, et al. Risk assessment in patients with acute myeloid leukemia and a normal karyotype. Clin Cancer Res. 2005;11:1416-24.
34. Suzuki T, Kiyoi H, Ozeki K, et al. Clinical characteristics and prognostic implications of NPM1 mutations in acute myeloid leukemia. Blood. 2005;106:2854-61.
35. Ozeki K, Kiyoi H, Hirose Y, et al. Biologic and clinical significance of the FLT3 transcript level in acute myeloid leukemia. Blood. 2004;103:1901-8.